Current Good Manufacturing Practice (cGMP)
The most up-to-date version of GMP requirements enforced by regulatory authorities. The 'current' prefix emphasises that manufacturers must use technologies and systems that are current, not outdated. cGMP compliance requires ongoing investment in facilities, training, and quality systems.
Technical Context
The 'current' emphasis means manufacturers must continuously adopt contemporary technological capabilities — using outdated but once-acceptable methods violates cGMP. FDA cGMP regulations (21 CFR Parts 210-211 for drugs, 21 CFR 600-680 for biologics) are legally enforceable. Key cGMP developments for peptide manufacturing include: process analytical technology (PAT — real-time process monitoring), quality by design (QbD — systematic understanding of process parameters affecting product quality), continuous manufacturing (moving from batch to continuous flow production), and advanced analytics (multiattribute methods for simultaneous quality attribute assessment). cGMP violations can result in: warning letters, import alerts (blocking products at US borders), consent decrees (court-ordered compliance obligations), seizure of products, injunctions, and criminal prosecution for willful violations.